This week I'm joined by Dr Hirsh Trivedi, a transplant hepatologist and Director of the Metabolic Liver Program at Dell Medical School, UT Austin. He is board certified in internal medicine, gastroenterology, transplant hepatology, and obesity medicine. You can have a normal waistline and still be quietly storing harmful amounts of fat in your liver. Hirsh explains how fatty liver progresses, which tests are worth asking for, and how exercise, meal timing, sleep and food quality can change the trajectory. What we cover What lean MASLD is and why a normal BMI is not enough How fat leads to inflammation, scarring and cirrhosis, and why it can be reversed Fasting insulin, HOMA-IR, ApoB and the FIB-4 score Why exercise helps your liver independent of weight loss Why breakfast and lunch should be bigger than dinner Sleep, stress and sleep apnoea GLP-1 medications, muscle loss and grey market peptides If you want to understand what is happening in the organ at the centre of your metabolic he
This week I'm joined by Dr Eric Helms, a sports scientist, coach, and WNBF pro natural bodybuilder with more than 20 years of drug-free training behind him. He co-founded MASS Research Review and co-directs the Sports Research Institute New Zealand at the Auckland University of Technology. Most lifters who stall assume they have hit their genetic limit. Eric explains why that is rarely the case, why gains diminish the longer you train, and how to decide what progress is actually worth to you. What we cover Why a genetic ceiling is not a single fixed number How much progress is realistic after the beginner years Why women and men gain muscle at similar relative rates What steroid use does and does not leave behind How many sets, reps, and how close to failure suit busy lifters in their 40s and 50s Supersets, drop sets, and tracking your own training If you want a more honest framework for your training, this one is for you. If you enjoy the show, a rating or review on Apple Podcasts goe
Elizabeth Kazarian is a physician double board-certified in Family Medicine and Obesity Medicine, practising in Washington DC. She treats obesity for a living, which means she spends as much time on insurance appeals as she does on clinical decisions. Roughly one in ten American adults now reports using a GLP-1 medication, and the public conversation has split between people calling them a shortcut and people calling them a miracle. Elizabeth occupies the far more useful middle ground, and she is candid about where the evidence is strong, where it is thin, and where the real obstacles lie. What We Cover Why treating obesity means treating the brain, and what that does to the willpower argument Why she stopped asking patients to earn medication through failed dieting What happens when people come off these drugs, including the part of the data nobody quotes The insurance and rebate machinery that decides which GLP-1 you are offered BMI, body composition, and working with a tool whose se